Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Bernhard Volz"'
Autor:
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Publikováno v:
Breast, Vol 54, Iss , Pp 88-95 (2020)
Purpose: Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor–positive, HER2-negative (HR + HER2–) breast cancer (BC). However, real-world data on the implementation of th
Externí odkaz:
https://doaj.org/article/06b4953fd7094428a800955c7f592096
Autor:
Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. Howe
Externí odkaz:
https://doaj.org/article/3595f6bd2f1948ae89b5ca12ff495d0f
Autor:
Hanna Huebner, Peter A. Fasching, Walter Gumbrecht, Sebastian Jud, Claudia Rauh, Mark Matzas, Peter Paulicka, Katja Friedrich, Michael P. Lux, Bernhard Volz, Paul Gass, Lothar Häberle, Franziska Meier-Stiegen, Andreas Hartkopf, Hans Neubauer, Katrin Almstedt, Matthias W. Beckmann, Tanja N. Fehm, Matthias Ruebner
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background The assessment of circulating tumor cells (CTCs) has been shown to enable monitoring of treatment response and early detection of metastatic breast cancer (MBC) recurrence. The aim of this study was to compare a well-established C
Externí odkaz:
https://doaj.org/article/bfd317d8ccf64d408ee42d08b0da35cb
Autor:
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Publikováno v:
Breast, Vol 55, Iss , Pp 138-139 (2021)
Externí odkaz:
https://doaj.org/article/3ce18d162da74f4b92ea7082883a3131
The method of soil washing is currently the only economically feasible cleaning method for PFAS-contaminated soils on large scale.A total of about 430,000 t of soil contaminated with PFAS and HCs was washed from August 2018 to October 2021 at the sit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e87f7e7942c8e7473c3cc09c102b69f
https://doi.org/10.5194/egusphere-egu23-1373
https://doi.org/10.5194/egusphere-egu23-1373
Autor:
Liewei Wang, Richard M. Weinshilboum, Scott H. Kaufmann, Cristina Correia, Michael A. Walters, Matthew E. Cuellar, Barbara Goodnature, Matthew P. Goetz, Tufia Haddad, Erin E. Carlson, Poulami Barman, Bernhard Volz, Bingshu E. Chen, Paul E. Goss, Matthew J. Ellis, Krishna R. Kalari, Zeruesenay Desta, Ravinder J. Singh, Tanya L. Hoskin, Peter A. Fasching, Lois E. Shepherd, Vera J. Suman, Junmei Cairns, James N. Ingle
Purpose:To determine if the degree of estrogen suppression with aromatase inhibitors (AI: anastrozole, exemestane, letrozole) is associated with efficacy in early-stage breast cancer, and to examine for differences in the mechanism of action between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::863cc18ace5c45681a8e51a753a51ac2
https://doi.org/10.1158/1078-0432.c.6530129.v1
https://doi.org/10.1158/1078-0432.c.6530129.v1
Autor:
Liewei Wang, Richard M. Weinshilboum, Scott H. Kaufmann, Cristina Correia, Michael A. Walters, Matthew E. Cuellar, Barbara Goodnature, Matthew P. Goetz, Tufia Haddad, Erin E. Carlson, Poulami Barman, Bernhard Volz, Bingshu E. Chen, Paul E. Goss, Matthew J. Ellis, Krishna R. Kalari, Zeruesenay Desta, Ravinder J. Singh, Tanya L. Hoskin, Peter A. Fasching, Lois E. Shepherd, Vera J. Suman, Junmei Cairns, James N. Ingle
This file is the revised clean Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::628f1d65cb215164fa22d2124af0f093
https://doi.org/10.1158/1078-0432.22479095
https://doi.org/10.1158/1078-0432.22479095
Autor:
Matthias W. Beckmann, Lothar Häberle, Christoph Thomssen, Michael P. Lux, Rachel Wuerstlein, Michael Untch, Friedrich Overkamp, Peyman Hadji, Tanja Fehm, Bernhard Volz, Erik Belleville, Alexander Hein, Wolfgang Janni, Hans Tesch, Andreas Schneeweiss, Lena A. Wurmthaler, Christian M. Kurbacher, Johannes Ettl, Carsten Hielscher, Florin-Andrei Taran, Volkmar Müller, Andreas D. Hartkopf, P Wimberger, Sara Y. Brucker, Hans-Christian Kolberg, Diana Lüftner, Diethelm Wallwiener, Peter A. Fasching, Julius Emons, Markus Wallwiener
Publikováno v:
European Journal of Cancer. 155:1-12
Purpose Assessment of HER2 overexpression using immunohistochemistry (IHC) and/or in situ hybridisation (ISH) for the detection of HER2 amplifications is standard to identify patients for established HER2-directed treatments. Patients with lower HER2
Autor:
Peter A. Fasching, Achim Wöckel, Hans Tesch, Bernhard Volz, Uwe Pritzsche, Marc Bachmann, Asmir Vodencarevic, Julia Kreuzeder, Diana Lüftner
Publikováno v:
Cancer Research. 83:P4-01
Background: Predicting the probability of tumor progression and tolerability with sufficient accuracy remains a significant challenge in advanced breast cancer. The objective of AI4ANNA study was to assess the predictive potential of machine learning
Autor:
Scott H. Kaufmann, James N. Ingle, Paul E. Goss, Michael A. Walters, Cristina Correia, Bingshu E. Chen, Matthew E. Cuellar, Tanya L. Hoskin, Matthew J. Ellis, Liewei Wang, Bernhard Volz, Ravinder J. Singh, Vera J. Suman, Richard M. Weinshilboum, Barbara Goodnature, Junmei Cairns, Krishna R. Kalari, Tufia C. Haddad, Matthew P. Goetz, Zeruesenay Desta, Erin E. Carlson, Poulami Barman, Peter A. Fasching, Lois E. Shepherd
Publikováno v:
Clin Cancer Res
Purpose:To determine if the degree of estrogen suppression with aromatase inhibitors (AI: anastrozole, exemestane, letrozole) is associated with efficacy in early-stage breast cancer, and to examine for differences in the mechanism of action between